The short version
When a periodontist hears "peptides," two very different things are in the room. One is a set of FDA-regulated biologics that periodontists have used in intrabony defects for decades. The other is the compounded injectable peptides patients read about online. They share a word and almost nothing else. This guide separates them, use by use, with every study verified on PubMed and every regulatory status read on an FDA page.
The full tables, including bone and implants, oral mucosa, post-surgical healing, and enamel, are in the dental evidence guide. This article covers periodontal regeneration only.
Educational only. PeptIQ.io does not sell, source, or dispense peptides. Study summaries describe what was studied and what the authors reported, never what a product does for a patient. No dosing appears here.
What "FDA-approved" means in this context
The approved periodontal biologics are devices cleared through premarket approval (PMA), not drugs, and certainly not compounded preparations. That distinction matters for a practice: a PMA device has an indication statement, a manufacturer, and an ordinary dental supply chain. A compounded peptide has none of those; it has a pharmacy's willingness to compound it and whatever FDA has said about the bulk substance.
Enamel matrix derivative (Emdogain)
- Regulatory status: FDA premarket approval P930021, decision date September 30, 1996. FDA supplement records later added mandibular Class II furcation and gingival recession indications (2003) and use with bone substitutes (2009).
- Strongest evidence: the Cochrane review (Esposito 2009, 13 RCTs) and a 2026 meta-analysis of 67 RCTs (Miron and Sculean, 2,552 participants) both land on roughly 1 mm of added clinical attachment gain and pocket reduction in intrabony defects over flap surgery alone. The Cochrane authors flagged high heterogeneity and possible overestimation.
- The original trial: Heijl 1997, a 33-patient split-mouth RCT, reported greater attachment and radiographic bone gain than placebo through 36 months.
- Where it is weaker: furcation evidence rests on one 10-patient split-mouth RCT (Chitsazi 2007). For root coverage, a 2021 meta-analysis found moderate-certainty benefit when added to a coronally advanced flap, while the 2026 review called the gains modest and not statistically significant.
rhPDGF-BB with beta-TCP (GEM 21S)
- Regulatory status: FDA premarket approval P040013, November 18, 2005, indicated for intrabony and furcation periodontal defects and gingival recession associated with periodontal defects. It is a recombinant growth-factor protein, not a short peptide.
- Strongest evidence: the 180-patient pivotal RCT (Nevins 2005) reported faster attachment gain and markedly more radiographic bone fill than the carrier alone at six months; the 36-month follow-up (Nevins 2013) found a higher share of treated defects meeting a composite success benchmark. A 2015 meta-analysis pooled about 1 mm of extra linear defect fill, noting only one included study was at low risk of bias.
P-15 peptide on anorganic bovine mineral (PepGen P-15)
This one is the cautionary tale about reading FDA pages rather than product memories.
- Regulatory status: FDA premarket approval P990033 was granted October 25, 1999 for intrabony defects due to moderate or severe periodontitis. The same FDA record shows a withdrawal date of February 16, 2016. We found no current US dental authorization for P-15.
- Evidence: two RCTs by Yukna (1998, 2000) associated the product with greater defect fill than allograft or debridement alone, and the 2000 trial isolated the peptide's contribution over the mineral carrier. A 2020 meta-analysis pooled about 1.4 mm more attachment gain than open flap debridement in intrabony defects, with no significant difference for furcation or recession defects.
Strong historical evidence, no ordinary US supply chain today. That is why it sits at amber in our tables rather than green.
An approved drug studied off-label: teriparatide
Teriparatide (Forteo) is an FDA-approved drug under NDA 021318 for osteoporosis indications only. Nothing on the label is dental.
The one periodontal trial is Bashutski et al., NEJM 2010: a 40-patient, NIH-funded RCT in which systemic teriparatide given around periodontal surgery was associated with greater radiographic bone gain and better clinical outcomes than placebo at one year. It has not been replicated at scale, and the trial registry (NCT00277706) shows no successor periodontitis trial. Interesting, small, and entirely off-label.
Approved drugs with observational dental signals: GLP-1 receptor agonists
Semaglutide, tirzepatide, and liraglutide are approved for diabetes and obesity indications, not for anything dental. The periodontal literature is real but indirect: a 2026 TriNetX cohort of about 98,000 matched patients per arm associated tirzepatide with fewer recorded periodontal and oral events than GLP-1 receptor agonists, and rat ligature models of liraglutide (Sawada 2020, Zhang 2020) reported less bone loss, while an exenatide rat study (Moraes 2015) did not. Two 2026 reviews (Nijakowski; Polymeri, Giannobile and Loos) agree no clinical trial has tested a periodontal outcome.
The compounded peptides patients ask about
This is where honesty is the product.
